Salivary testosterone: Associations with depression, anxiety disorders, and antidepressant use in a large cohort study  by Giltay, Erik J. et al.
Journal of Psychosomatic Research 72 (2012) 205–213
Contents lists available at SciVerse ScienceDirect
Journal of Psychosomatic ResearchSalivary testosterone: Associations with depression, anxiety disorders, and
antidepressant use in a large cohort study
Erik J. Giltay a,⁎, Dorien Enter b, Frans G. Zitman a, Brenda W.J.H. Penninx a,c,d, Johannes van Pelt e,
Phillip Spinhoven b, Karin Roelofs b
a Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
b Institute of Psychology, Leiden University, Leiden, The Netherlands
c Department of Psychiatry, VU University Medical Centre, Amsterdam, The Netherlands
d Department of Psychiatry, University Medical Centre Groningen, The Netherlands
e Laboratory for KCHI, Medical Center Alkmaar, Alkmaar, The Netherlands⁎ Corresponding author at: Leiden University Medical
atry, P.O. Box 9600, 2300RC, Leiden, The Netherlands. Te
71 5248156.
E-mail address: e.j.giltay@lumc.nl (E.J. Giltay).
0022-3999 © 2011 Elsevier Inc.
doi:10.1016/j.jpsychores.2011.11.014
Open access under the Elsea b s t r a c ta r t i c l e i n f oArticle history:
Received 7 September 2011
Received in revised form 21 November 2011
Accepted 22 November 2011
Keywords:
Salivary testosterone
Depression
Anxiety disorders
Antidepressants
Social phobia
Androgens
Objective: Low circulating levels of testosterone have been associated with major depression, but there is
more limited evidence for differences in patients with anxiety disorders. The use of selective serotonin reup-
take inhibitors (SSRIs) and other antidepressants is associated with sexual side effects, warranting testing for
interactions with testosterone.
Methods: Data are from 722 male and 1380 female participants of The Netherlands Study of Depression and
Anxiety (NESDA), who were recruited from the community, general practice care, and specialized mental
health care. Depressive and anxiety diagnoses were assessed using the DSM-IV Composite International Di-
agnostic Interview. To smooth the episodic secretion, the four morning saliva samples per participant and
the two evening samples were pooled before testosterone analysis.
Results: Morning median testosterone levels were 25.2 pg/ml in men and 16.2 pg/ml in women, with lower
evening levels of 18.2 and 14.1 pg/ml, respectively. Signiﬁcant determinants of testosterone levels were
sex, age, time of the day, use of contraceptives, and smoking status. Female patients with a current
(1-month) depressive disorder (effect size 0.29; P=0.002), generalized anxiety disorder (0.25; P=0.01), so-
cial phobia (0.30; Pb0.001), and agoraphobia without panic disorder (0.30; P=0.02) had lower salivary tes-
tosterone levels than female controls. Higher testosterone levels were found in male and female participants
using SSRIs than in non-users (effect size 0.26; Pb0.001).
Conclusion: Salivary testosterone levels are lower in female patients with a depressive disorder, generalized
anxiety disorder, social phobia, and agoraphobia as compared to female controls. SSRIs may increase salivary
testosterone in men and women.© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
There are important sex differences in prevalence proportions of
psychiatric disorders, with women having a more than double the
risk of depressive disorder, generalized anxiety disorder, social phobia,
and panic disorders with or without agoraphobia [1–6]. Differences
between the sexes have also been found for symptom proﬁles of de-
pression, with an earlier age of onset, a higher symptom severity,
more atypical depression, and a diminished libido in affected women
compared tomen [1,4,7]. Libido and other sexual functionsmay further
worsen under the inﬂuence of antidepressant use [8,9]. Especially selec-
tive serotonin reuptake inhibitors (SSRI), generally preferred as theCenter, Department of Psychi-
l.: +31 71 5263448; fax: +31
vier OA license.ﬁrst-line pharmacotherapy treatments for mild to moderate outpatient
depression and anxiety disorders, are associated with sexual problems
such as diminished libido and difﬁculties with sexual arousal and or-
gasm in at least 30% of patients [8–10].
Testosterone is an important circulating androgen. Its secretion is
under the rapid pulsatile control of gonadotropin-releasing hormone
(GnRH), which in turn stimulates the production of luteinizing hor-
mone. Consequently, there are cyclic changes in serum testosterone
levels (with a slight nocturnal rise), and therefore ideally at least several
morning blood samples separated by 30-minute intervals are to be used
to assess androgenic status in ameaningful way [11]. Salivary testoster-
one levels are strongly correlated with free serum testosterone levels in
men [12,13], but less strongly in women, for whom there is less evi-
dence [14,15].
Testosterone is involved in male secondary sexual characteristics,
reproduction, and sexual function. The brain contains receptors for
testosterone [16–19], and is capable of synthesizing and metabolizing
206 E.J. Giltay et al. / Journal of Psychosomatic Research 72 (2012) 205–213testosterone to, for instance, estradiol [20–22]. In some studies, a low
androgen status has been associated with symptoms of fatigue, irrita-
bility, dysphoria, declining vigor, low vitality, sexual dysfunction in
men [23–26] and women [27], and an increased risk of depressive
symptoms and depression in most [28–30] but not all studies
[31,32]. Findings were mixed, however, as several other epidemiolog-
ical studies did not show or showed non-linear relationships between
testosterone levels and depressive symptoms [33]. Inconsistencies
may partly be due to the link or interaction with the genetic cyto-
sine–adenosine–guanine (CAG) repeat length polymorphism. Longer
CAG repeats may diminish the androgen receptor transactivation ca-
pacity and has been linked to the vulnerability to depression and anx-
iety [34,35], though not consistently [36–38]. Evidence on the role of
testosterone in women is scarce, but there is some evidence that low
DHEA(S) is involved in depression in women [39,40]. Androgen dep-
rivation therapy in men with prostate cancer induces many of these
symptoms, which are reversible after cessation of therapy [41,42].
However, androgen withdrawal induced adverse mood symptoms
only in a subgroup of 10% (3 out of 31) of healthy male volunteers
[43]. Low testosterone levels have also been found in men with dys-
thymic disorder [44]. In a large community sample of almost 4000 el-
derly men, free testosterone concentration in the lowest quintile was
associated with more depressive symptoms [29]. The evidence for a
potential role of testosterone in anxiety disorders ismuchmore limited.
Low salivary testosterone levels were associated with depressive and
anxiety symptoms in 106 adolescent boys but not in 107 girls [45] and
weakly with anxiety symptoms in 3413 men [32], but other studies
found no relationship between social anxiety and basal salivary testos-
terone levels in 20 adolescents [46] and 58 students [47]. Moreover, the
urine testosterone level was comparable in 16 patients with panic dis-
order versus 13 controls [48]. Even so, testosterone has been associated
with many behavioral aspects of dominance, competition, aggression,
and sociality [49–56].
Data on serum testosterone level in anxiety disorders is scarce,
whereas salivary testosterone levels have even less often been stud-
ied in small groups of patients with psychiatric disorders [57]. Also,
there are few studies on the effects of antidepressants on the hypo-
thalamic–pituitary–gonadal (HPG) axis [58]. We hypothesized that
low salivary testosterone levels are associated with both depressive
and anxiety disorders. Second, treatment of depressive and anxiety
disorders with antidepressants decreases libido and this may be due
to a reduction in testosterone levels. We measured salivary testoster-
one levels in the large Netherlands Study of Depression and Anxiety
(NESDA). A number of 4 morning and 2 evening salivary samples
were pooled before testosterone was quantiﬁed in order to minimize
the effects of the pulsatile release of testosterone [11,15]. The use of a
number of saliva samples had advantages over blood samples as they
are more easily collected by participants themselves at several time
points at their homes; it requires no pain- and stress-inducing veni-
punctures; and salivary testosterone reﬂects the free bio-available
serum fraction.
Method
Participants took part in NESDA [59], a large longitudinal cohort
study on the course of depressive and anxiety disorders. The NESDA
sample consists of 2981 participants (mean age 41.9, range 18–65;
1002 men and 1979 women), of whom 807 persons were recruited
through mental health care organizations, 564 persons through the
community setting and the remaining 1610 through primary care.
Exclusion criteria were a primary diagnosis of psychotic, obsessive–
compulsive, bipolar or severe addiction disorder and not being ﬂuent
in Dutch. The baseline assessment was constituted by a medical exam,
a face-to-face interview, saliva collection and several written question-
naires. Detailed objectives and methods of NESDA are described else-
where [59]. The research protocol was approved by the ethicalcommittee of participating universities, and all of the respondents pro-
vided written informed consent.
There were 2329 participants with a lifetime diagnosis of depressive
and/or anxiety disorder and 652 controls without a lifetime psychiatric
diagnosis. Controls were deﬁned as having no prior lifetime history of
anxiety disorder (i.e., panic disorder, generalized anxiety disorder, or
social phobia) or depressive disorder (i.e., major depressive disorder
(MDD) or dysthymia).
Assessment of psychopathology and antidepressant use
Several instruments were used to assess psychopathology. The
presence of a DSM-IV major depressive disorder or anxiety disorder
(i.e., panic disorder, social phobia, generalized anxiety disorder, and
agoraphobia) was assessed by the DSM-IV based Composite Interview
Diagnostic Instrument (CIDI, WHO Version 2.1). The presence of psy-
chiatric disorders within the past 12 months was used to categorize
participants into those with no lifetime anxiety of depressive disorder
(n=522), those with a remitted (b1 year) disorder (n=461), with a
recent (1-year) or current anxiety disorder (n=276), those with a
recent (1-year) or current depressive disorder (n=412) and a recent
or current comorbid disorder (n=471). We also analyzed current
psychiatric disorders within the preceding month for depressive dis-
order and anxiety disorders (i.e., social phobia, panic disorder and/or
agoraphobia, and generalized anxiety disorder). The total score of the
Inventory of Depressive Symptomatology Self Report (IDS-SR) was
used to assess overall depression severity,[60] and subdivided into
ﬁve severity groups, i.e., low (total score 0–13), mild (14–25), moder-
ate (26–38), severe (39–48), and very severe (49–84). Item 22 (i.e.,
interest in sex) from the IDS-SR was analyzed separately as an inter-
nal validation of the salivary testosterone assessment, that was rated
on a four-point scale: 0 (i.e., usual interest), 1 (i.e., somewhat less in-
terest or pleasure), 2 (i.e., little interest or pleasure), and 3 (i.e., no in-
terest or pleasure). The total score of the Beck Anxiety Inventory was
used to assess affective and somatic symptoms of anxiety, [61] and
subdivided into four severity groups, i.e., normal (total score 0–9),
mild (10–18), moderate (19–29), and severe (30–63) [62]. For
15-item Fear Questionnaire cut-off scores of 19 for the 5-item agora-
phobia AG subscale and 18 for 5-item social phobia (SO) subscale
were used [63].
Medication use during the month prior to baseline interview was
registered by observation of drug containers brought to the interview
or self-report. Using the World Health Organization Anatomical Ther-
apeutic Chemical classiﬁcation [64], psychoactive medication was
categorized into antidepressants (i.e., tricyclic antidepressants [TCA;
N06AA], SSRIs [N06AB], and other antidepressants [N06AF, N06AG,
N06AX]), and benzodiazepine use (N03AE, N05BA, N05CD, N05CF)
was dichotomized.
Salivary testosterone measurement
At baseline, respondents were instructed to collect saliva samples
at home on a regular (preferably working) day shortly after the inter-
view. The median time between the interview and saliva sampling
was 9 days (25th–75th percentile, 4–22 days). Instructions prohibited
eating, smoking, drinking, or brushing teeth within 15 min. Saliva sam-
ples were obtained using Salivettes (Sarstedt AG and Co., Nümbrecht,
Germany) at 6 time points: four morning samples (at awakening and
at 30, 45, and 60 min later) and 2 evening samples (at 22:00 h and
23:00 h). Indirect evidence suggests that compliance of participants to
the protocol was good, as the cortisol awakening response showed
the characteristic curve within the ﬁrst hour of awakening in the large
majority of participants, with a steep decline in both evening samples
[65]. Samples were stored in refrigerators and returned by regular
mail. After receipt, Salivettes were centrifuged at 2000 g for 10 min, ali-
quoted, and stored at −80 °C. Samples had been thawed once for the
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previously [65]. While storage at −80 °C of salivary samples does not
affect testosterone levels during at least two years, the extra freeze
thaw cycle may have contributed some error to testosterone measure-
ment [14]. Salivary testosterone levels have been shown to be relatively
stable over time, with a test–retest stability of 0.65 in men and 0.78 in
women over two weeks [66].
To smooth the episodic secretion [11,15], 75 μl of each of the 4
samples collected in the morning (at wake-up and after 30, 45 and
60 min) were mixed to yield one morning sample, and 150 μl of
each of the 2 evening samples collected at 22:00 and 23:00 h were
mixed to yield also one evening sample. So for every participant,
one mixed morning sample and one mixed evening sample were
assayed. If one of the samples was missing, a corresponding volume
of the other sample(s) was taken. The 11 subjects who did not pro-
vide any evening sample were excluded. For every other subject
who provided saliva, both a morning and evening sample could be
combined. Biochemical analysis of free testosterone in saliva was
measured in duplo by the testosterone in saliva assay from Diagnostic
Biochem Canada (EiAsy Testosterone Saliva, DBC: CAN-TE-300) using
2×100 μl material. The sensitivity of the kit is 1.0 pg/ml and there are
hardly cross-reactivities with other steroids. In every assay a standard
control was used, with a mean of 26.9 pg/ml (SD 2.1) that was repro-
ducible with a coefﬁcient of variation (CV) of 7.8%. The intra assay
precision was 7.1, 3.4, and 6.7% at the concentrations of resp. 14, 38
and 123 pg/ml (n=10). In our study about 120 kits were used, all
of the same lot. The CV over all testosterone measurements was
10.2%.
To validate the use of Salivettes for testosterone measurement, we
also compared saliva obtained though Salivettes with those obtained
through Salicaps (a passive drooling device) in a repeated-measures
design. We included 10 healthy volunteers (age 35 [SD 12] year; 5 fe-
males). Saliva was collected at 6 time-points with alternating Salicaps
(IBL International GMBH, Hamburg, Germany) (3 times) and Saliv-
ettes (Sarstedt, Newton, NC, USA) (3 times) with 10 min in between
and always starting with a Salicap. Participants were instructed to
minimize physical exercise and not to eat, drink or smoke, 1 h before
the start and during the sampling period. Moreover, to avoid cross-
contamination, participants were instructed to rinse the mouth with
pure water immediately after each sample (always 10 min before the
next sampling). All samples were frozen and after a single freeze–thaw
cycle centrifuged for 10 min at 5000 g to remove mucins and to extract
the saliva from the Salivettes. The three Salivette sampleswere also com-
bined to one sample (mixed sample), and the same was done for the
three Salicap samples. Testosterone was measured in duplo in every
sample as well as the mixed samples using the method described
above. There was a signiﬁcant higher testosterone level in saliva
obtained by Salivettes than by Salicaps (as was shown previously) [14],
but this differencewas highly constant. Pearson's correlation coefﬁcients
between the individuals' mean values obtained with Salivettes and Sali-
caps were r=0.87 (pb0.001) for the calculated mean and r=0.87
(pb0.001) for the measured value from the mixed samples. Using
ranked-order Spearman's correlation coefﬁcients similar ﬁndings were
obtained (r=0.82 and r=0.82, respectively).
Potential covariates
Sociodemographic factors included sex, age, and educational level
(years of attained education). Age was categorized by decade. Body
mass index (BMI) was calculated as weight divided by length squared,
and categorized into 4 groups (b20 kg/m2/20 to 25 kg/m2/25 to
30 kg/m2/≥30 kg/m2). Smoking status was dichotomized into non-
smoker or current smoker. Alcohol consumption was categorized into
3 groups (i.e., non-user/a number of units of alcohol of less than 2 per
day/2 or more per day). Physical activity was assessed using the Inter-
national Physical Activity Questionnaire (Craig et al., 2003) andexpressed per 1000 Metabolic Equivalent of Task (MET)/min a week,
and subsequently categorized into 3 groups (i.e., b3/3 to 6/≥6 of
1000 MET/min per week). A MET/min is deﬁned as the metabolic
equivalent of the number of calories consumed by a person (of 60 kg)
per minute in an activity relative to the basal metabolic rate (www.
ipaq.ki.se), and≥3 indicates activities of at leastmoderate intensity. Re-
spondents reported working status on the sampling day (i.e., whether
(61.8%) or not (38.2%) the participant went to their job that day). Sam-
pling data was used to categorize weekday versus weekend day and
season, whichwas categorized into darkmonths (i.e., October to Febru-
ary) and months with more daylight (i.e., March through September).
For subgroup analyses in women, information on the use of oral
contraceptives and on menstrual phase was obtained. Duration of
the menstrual cycle and the number of days since the last menstrua-
tion were used to yield the phase of the menstrual cycle at the time of
saliva sampling for women reporting a menstrual cycle between 28
and 32 days (i.e., 0–3 days of cycle was regarded as the early follicular
phase, 4–13 days as the late follicular phase, and 14–32 days as the
luteal phase). Remaining women were categorized as either using
oral contraceptives or being post-menopausal.
Prevalent cardiovascular diseases (i.e., coronary disease, cardiac
arrhythmia, angina pectoris, heart failure, and myocardial infarction)
were ascertained using an algorithm based on self-report data and
medication use.
Statistical analysis
The distributions of morning and evening salivary testosterone
levels were strongly positively skewed and therefore naturally log-
transformed values were used for analyses. Back-transformed geo-
metric mean values are presented in tables and ﬁgure. Pearson's cor-
relation coefﬁcients were used to analyze the relationship between
morning and evening salivary testosterone levels. Univariate analysis
of variance was performed to evaluate the effects of sociodemographic
factors, health indicators, and sampling factors on salivary testosterone
levels, for morning and evening testosterone levels separately.
Because the morning and evening samples were highly intercorre-
lated, showing highly comparable associations with psychiatric char-
acteristics, analyses reported in the paper were conducted over
individual means of the z-scores of morning and evening samples.
The effects of psychiatric characteristics and psychotropic medication
on testosterone levels were analyzed in unadjusted and adjusted an-
alyses of (co)variance (adjusted for sex, age, menstrual status, years
of education, smoking status, prevalent cardiovascular disease, and
northern European ancestry), in men and women separately. When
analyzing the associations with psychopathology measures, we also
adjusted for SSRI use, because of its strong association with salivary
testosterone levels.
Two-tailed P values of less than 0.05 were considered to indicate
statistical signiﬁcance. For signiﬁcant ﬁndings, effect sizes were calcu-
lated with Cohen's d. All of the analyses were conducted using SPSS
version 17.0 statistical software (SPSS Inc, Chicago, Illinois).
Results
Participants
The 722men were on average 45.0 (range 18 to 64) years old and the 1380 women
42.7 (range 18 to 65) (Table 1). The mean BMI was 26.2 kg/m2 for men and 25.3 for
women, and around 17% of men and women were obese (i.e., BMI ≥30 kg/m2). Men
were more often current smokers and consumed more often ≥2 units of alcohol per
day than women. The prevalence of cardiovascular disease was approximately double
in men versus women. There was a large range of salivary testosterone levels, that im-
portantly overlapped in men and women. Nevertheless, men had higher median sali-
vary testosterone levels than women both in the morning and evening samples
(Table 1). Testosterone levels showed rank-order stability within each gender between
morning and evening samples, with Spearman's rank correlation coefﬁcients of 0.62 in
men and also 0.62 in women.
Table 1
Characteristics in 2102 participants, according to sex.
Variables Men (N=722) Women (N=1380)
Age — year 44.9±12.6 42.8±13.2
Education — year 12.2±3.3 12.4±3.3
Northern European ancestry (no., %) 692 (95.8%) 1313 (95.1%)
Body-mass index — kg/m2
Mean 26.2±4.4 25.3±5.1
≥30 — no. (%) 127 (17.6%) 226 (16.4%)
Current smoker (no., %) 272 (37.7%) 426 (30.9%)
Alcohol consumption ≥2 units/d (no., %) 181 (25.1%) 166 (12.0%)
Physical activity — 1000 MET-min/week
(median, IQR)
2.83 (1.37–4.88) 3.08 (1.53–4.95)
Prevalent cardiovascular disease (no., %) 70 (9.8%) 63 (4.6%)
Salivary testosterone level — pg/ml
Morning (geometric mean, 95% CI) 25.7 (24.5–27.1) 17.7 (17.0–18.5)
Evening (geometric mean, 95% CI) 19.4 (18.4–20.5) 14.9 (14.1–15.6)
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The associations between age, menstrual status in women, health indicators (BMI,
smoking, alcohol intake, and physical activity), and sampling factors (working status
and season with more daylight) on salivary testosterone levels were analyzed as po-
tential correlates may be considered as covariates in epidemiological association stud-
ies. In men and women, age was strongly and inversely associated with both morning
and evening salivary testosterone levels (all Psb0.001). The lowest levels were found
in men and women over age 50. Current smoking was associated with high salivary
testosterone levels, especially for evening levels and more strongly so in women
than in men. Although the menstrual status showed an association with salivary tes-
tosterone, this did not persist after adjustment for covariates (e.g., age, smoking status,
and SSRI use; P=0.20), but in post-hoc comparisons women using oral contraceptives
(that increases SHBG which binds testosterone) had lower testosterone levels than
premenopausal women not using oral contraceptives (P=0.03). No univariate associ-
ations were found with other potential determinants.
Salivary testosterone, psychopathology and antidepressant use
We combined the morning and evening testosterone levels using the mean of z-
scores, because morning and evening levels were intercorrelated and associations
with measures of psychopathology were highly consistent for morning and evening
testosterones in both men and women (data not shown). Tables 2 and 3 show
the associations with measures of psychopathology and medication use separately in
men and women, respectively.
In adjusted models in men, there were no associations with measures of psychopa-
thology (Table 2). Those 106 men using SSRIs had higher testosterone levels than 558
men not using antidepressants (effect size 0.207; P=0.05). When repeating our anal-
ysis in men with recent (1 year) or current psychopathology the mean difference did
not importantly change (92 versus 245 men; effect size 0.192).
In adjustedmodels inwomen, there was a group differencewhen taking into account
the 12-month diagnostic status in adjusted analyses, indicating thatwomenwith any psy-
chiatric disorder had on average a lower testosterone level. When zooming in on the
1-month diagnostic categories, the female patients with a current depressive disorder
(P=0.002), current generalized anxiety disorder (P=0.01), current social phobia
(Pb0.001), current agoraphobia (without panic disorder; P=0.02) had lower testoster-
one levels than the reference group of female participants having no lifetime history of de-
pressive or anxiety disorder. The effect sizes were 0.287, 0.251, 0.299 and 0.304 for the
depressive disorder, generalized anxiety disorder social phobia, and agoraphobia, respec-
tively, indicating modest strengths. Again, more markedly increased testosterone levels
were found in 224 women using SSRI's than 1052 non-users of antidepressants (effect
size: 0.273; Pb0.001), but not in women using TCAs or other antidepressants. When re-
peating our analysis in women with recent (1 year) or current psychopathology the
mean difference did increase slightly (184 versus 475 women; effect size 0.335). In
women, the severity of anxiety symptoms (P=0.001), agoraphobia (effect size 0.175;
P=0.04), and social phobia (effect size 0.294; Pb0.001)was related to lower testosterone
levels. There was a linear trend for decreasing testosterone levels with increased social
phobia scores (Fig. 1). The comparison between the groups with severe anxiety versus
no anxiety yielded an effect size of 0.254. Although, there was also a difference between
categories of severity of depressive symptoms (P=0.03), thiswas not a linear association.
Because associations between SSRI use and salivary testosterone levels were compa-
rable in men and women (combined effect size 0.258), we further explored the effects of
antidepressants in all subjects combined. In adjusted analyses, SSRI users but not users of
TCAs or other antidepressants showed higher salivary testosterone levels than non-users
of antidepressants (Fig. 1). In post-hoc tests, we found that differences were statistically
signiﬁcant for ﬂuvoxamine and paroxetine, although differences for sertraline, ﬂuoxetine
and citalopram showed a similar tendency that did not reach signiﬁcance. The mean tes-
tosterone difference between SSRI users and non-users of antidepressants was of similarstrength in subjects with remitted disorders and current disorders (0.234 versus 0.268,
respectively).
Discussion
We found that depressive disorder, generalized anxiety disorder,
social phobia, and agoraphobia were associated with lower salivary
testosterone levels in women, but not in men. Remarkably, SSRI use
was associated with elevated testosterone levels in both men and
women. While morning testosterone levels were higher than evening
testosterone levels, we found that within-person correlation indicated
rank-order stability over the day. Our study therefore provides support
for the usefulness, validity and reliability of the noninvasive method of
testosterone measurement in saliva. It also points to the importance of
taking confounding variables into account, especially of sex, age, men-
strual cycle, time of the day, and smoking status. The associations be-
tween smoking and physical activity with higher testosterone levels
[67] and between oral contraceptive use and lower testosterone levels
[66,68] are in line with previous ﬁndings.
Testosterone levels were lower in female patients with current de-
pression versus female controls. Previous studies in women are rela-
tively scarce [27], in part because blood levels of free testosterone in
women were rather unreliable [69], until recently. Previous studies
in men [23–26,28–30] found lower testosterone levels in men with
depressive symptoms compared to male controls, which we could
not conﬁrm. Some previous epidemiological studies found no rela-
tionship between low testosterone and depressive symptoms
[31,32]. However, androgen activity is not only the effect of bioavail-
able androgens but also the responsiveness of the androgen receptor
in target cells. The androgen receptor gene (located on the X chromo-
some) contains a polymorphic CAG repeat sequence affecting andro-
gen sensitivity. Previous studies yielded inconsistent results; CAG
repeat length and depressive symptoms were positively associated
[35], unrelated [36], or associated only in subgroups of black men
[37] or patient groups [38]. In another study, low testosterone levels
were associated with depressive symptoms in men with short CAG re-
peat lengths only [34]. As we did not take into account the CAG repeat
length polymorphism, this may explain our null-ﬁnding in depressed
men. Trials with testosterone administration showed inconsistent evi-
dence for antidepressant properties, more so in hypogonadal than in
eugonadal men [33]. These studies were done in participants who did
[70–72] or did not [73] suffer from a depressive disorder. In supraphy-
siologic dosages, testosterone may induce euphoria and other symp-
toms of hypomania [74,75].
Yet, we included twice as many women than men in our study.
Our ﬁndings of low testosterone levels in social anxiety disorder, gen-
eralized anxiety disorder, and agoraphobia are not in line with the
previous smaller studies that found no relationship between social
anxiety and basal salivary testosterone levels [46,47]. Yet, among
the psychiatric disorders under study, particularly those that were
characterized by social withdrawal (i.e., depression, social anxiety
and agoraphobia) and high social anxiety scores were associated
with low testosterone levels in women. No association with panic dis-
order was found. These ﬁndings ﬁt previous notions that reduced tes-
tosterone was particularly evident for those primates and humans
who behaved socially submissive and showed increased levels of social
fear behavior, such as social withdrawal [49–52,54–56]. This could sug-
gest that low testosterone is rather a consequence than a cause of the
affective symptoms.
Nevertheless, there are putative biologicalmechanisms that point to a
causal role of low testosterone. First, affective symptoms are importantly
mediated by the ‘fear network’ involving the amygdala, hippocampus,
and prefrontal cortex, while exogenous and endogenous testosterones
signiﬁcantly modulated local activity and interregional connectivity in
the prefrontal cortex and the amygdala during social affective behavior
[53,76]. Neurons in the amygdala [16,19], hippocampus [17,18] and
Table 2
Forest plot for mean standard scores of salivary testosterone levels according to psychiatric characteristics in 722 male subjects.
Never
Remitted disorder
Anxiety disorder
Depressive disorder
Comorbid disorder
Unadjusted Adjusted*Variables
Tricyclic antidepressant
Selective serotonin reuptake inhibitor
Other antidepressant
No use
Present use
None
Mild
Moderate
Severe
Verysevere
None
Mild
Moderate
Severe
No. Mean (SE) P Mean(SE) P
Usualinterest
Somewhat less interest or pleasure
Little interest or plesaure
No interest or pleasure
No use
Never
Depressive disorder
Generalized anxiety disorder
Panic disorder with agoraphobia
Social phobia
Panic disorder without agoraphobia
Agoraphobia
No agoraphobia
Agoraphobia (≥ 19 on AG subscale)
No social phobia
Social phobia (≥ 18 on SO subscale)
200 −0.133 (SE0.053) 0.03 −0.098 (SE0.058) 0.14
132 −0.022 (SE0.071) 0.013 (SE0.068)
93 0.123 (SE0.086) 0.104 (SE0.082)
139 0.118 (SE0.070) 0.095 (SE0.067)
158 0.006 (SE0.061) −0.038 (SE0.065)
200 −0.133 (SE0.053) −0.103 (SE0.057)
98 0.043 (SE0.087) 0.07 −0.030 (SE0.087) 0.51
103 0.008 (SE0.072) 0.12 −0.005 (SE0.083) 0.25
135 −0.006 (SE0.068) 0.14 −0.066 (SE0.071) 0.76
71 0.095 (SE0.085) 0.03 0.034 (SE0.103) 0.24
40 0.098 (SE0.123) 0.08 0.119 (SE0.136) 0.09
37 −0.225 (SE0.136) 0.50 −0.176 (SE0.140) 0.86
426 −0.043 (SE0.036) 0.20 −0.042 (SE0.039) 0.18
210 0.097 (SE0.060) 0.097 (SE0.055)
56 −0.028 (SE0.097) −0.040 (SE0.106)
18 −0.080 (SE0.247) −0.115 (SE0.191)
558 −0.017 (SE0.034) 0.04 −0.008 (SE0.033) 0.04
12 −0.178 (SE0.145) −0.193 (SE0.225)
106 0.177 (SE0.080) 0.156 (SE0.077)
46 −0.171 (SE0.101) −0.215 (SE0.116)
624 −0.004 (SE0.032) 0.79 −0.002 (SE0.032) 0.97
98 0.019 (SE0.077) 0.002 (SE0.081)
282 −0.016 (SE0.047) 0.21 0.013 (SE0.048) 0.44
187 −0.069 (SE0.060) −0.067 (SE0.058)
161 0.124 (SE0.063) 0.084 (SE0.063)
65 −0.058 (SE0.091) −0.075 (SE0.098)
23 0.049 (SE0.173) −0.022 (SE0.175)
400 −0.030 (SE0.039) 0.42 −0.014 (SE0.040) 0.50
161 −0.023 (SE0.067) −0.044 (SE0.063)
116 0.107 (SE0.075) 0.095 (SE0.074)
41 0.025 (SE0.118) −0.034 (SE0.127)
652 −0.017 (SE0.031) 0.13 −0.017 (SE0.031) 0.18
66 0.137 (SE0.106) 0.123 (SE0.099)
555 −0.032 (SE0.033) 0.06 −0.022 (SE0.033) 0.27
158 0.100 (SE0.066) 0.058 (SE0.064)
6–month diagnosis of psychopathology
-0.4 -0.2 0.0 0.2 0.4 -0.4 -0.2 0.0 0.2 0.4
Sexual interest**
Benzodiazepine use
Fear questionnaire
Antidepressant use
Inventory of depressive symptomatology
Beck’s anxiety inventory
1–month diagnosis versus never–diagnosis of psychopathology
The size of each square is proportional to the number of participants; horizontal lines indicate standard errors.
Standard scores were calculated as the mean of z-scores of the morning and evening testosterone levels, within each sex.
P values are for the difference between the groups by analysis of variance.
⁎Adjusted for age, years of education, smoking status, prevalent cardiovascular disease, and northern European ancestry (as well as SSRI use [2 categories] when appropriate).
⁎⁎Sexual interest was assessed with item 22 of the Inventory of Depressive Symptomatology Self Report (IDS-SR).
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there may be an imbalance between testosterone and cortisol [56,77].
Androgens may downregulate the hypothalamo–pituitary–adrenal
(HPA) axis in a direct way via androgen receptors which are expressed
in corticotropin-releasing factor (CRF) producing neurons in the hypo-
thalamus and which suppressed the promoter region of the CRF gene
[17,18]. Elevated plasma cortisol levels and hyperactivity of CRFneurons in the paraventricular nucleus (PVN) of the hypothalamus
are consistent neurobiological ﬁndings in depressive and anxiety disor-
ders [17,65,78,79], and the expression of androgen receptors is low in
post-mortem brain tissue from patients with depression [17]. There-
fore, our ﬁndings ﬁt with the idea that low bioavailable testosterone in-
creases the risk to several psychiatric disorders, that social anxiety and
submission induces a lowering of androgens, or both.
Table 3
Forest plot for mean standard scores of salivary testosterone levels according to psychiatric characteristics in 1380 female subjects.
Never
Remitted disorder
Anxiety disorder
Depressive disorder
Comorbid disorder
Tricyclic antidepressant
Selective serotonin reuptake inhibitor
Other antidepressant
No use
Present use
None
Mild
Moderate
Severe
Very severe
None
Mild
Moderate
Severe
Usual interest
Somewhat less interest or pleasure
Little interest or plesaure
No interest or pleasure
No use
Never
Depressive disorder
Generalized anxiety disorder
Panic disorder with agoraphobia
Social phobia
Panic disorder without agoraphobia
Agoraphobia
No agoraphobia
Agoraphobia (≥19 on AG subscale)
No social phobia
Social phobia (≥18 on SO subscale)
307 0.084 (SE 0.051) 0.23 0175 (SE 0.054) 0.009
320 − 0.086 (SE 0.045) − 0.015 (SE 0.052)
177 − 0.027 (SE 0.079) − 0.082 (SE 0.070)
267 − 0.016 (SE 0.063) − 0.041 (SE 0.056)
309 0.035 (SE 0.057) − 0.068 (SE 0.054)
307 0.084 (SE 0.051) 0.139 (SE 0.053)
181 − 0.056 (SE 0.073) 0.11 − 0.151 (SE 0.072) 0.002
145 − 0.038 (SE 0.081) 0.19 − 0.131 (SE 0.082) 0.01
252 − 0.091 (SE 0.061) 0.03 − 0.161 (SE 0.061) < 0.001
156 0.177 (SE 0.084) 0.32 0.013 (SE 0.083) 0.15
51 0.032 (SE 0.119) 0.69 0.003 (SE 0.130) 0.55
73 − 0.221 (SE 0.135) 0.01 − 0.220 (SE 0.116) 0.02
690 0.025 (SE 0.035) 0.09 0.030 (SE 0.036) 0.06
298 0.070 (SE 0.058) 0.072 (SE 0.053)
251 − 0.117 (SE 0.061) − 0.100 (SE 0.059)
111 − 0.072 (SE 0.089) − 0.131 (SE 0.089)
1052 − 0.044 (SE 0.029) 0.001 − 0.040 (SE 0.028) 0.002
36 − 0.008 (SE 0.174) 0.061 (SE 0.154)
224 0.242 (SE 0.063) 0.215 (SE 0.062)
68 − 0.098 (SE 0.097) − 0.116 (SE 0.112)
1176 0.009 (SE 0.028) 0.40 0.013 (SE 0.027) 0.29
204 − 0.051 (SE 0.065) − 0.063 (SE 0.066)
475 0.025 (SE 0.041) 0.50 0.094 (SE 0.043) 0.03
423 0.013 (SE 0.049) 0.017 (SE 0.045)
326 − 0.064 (SE 0.053) − 0.121 (SE 0.051)
112 − 0.018 (SE 0.098) − 0.083 (SE 0.089)
39 0.181 (SE 0.142) 0.021 (SE 0.149)
689 0.041 (SE 0.037) 0.10 0.101 (SE 0.036) 0.001
394 − 0.100 (SE 0.046) − 0.121 (SE 0.046)
218 0.031 (SE 0.065) − 0.034 (SE 0.063)
76 0.067 (SE 0.107) − 0.142 (SE 0.109)
1216 0.002 (SE 0.027) 0.90 0.022 (SE 0.026) 0.04
161 − 0.008 (SE 0.076) − 0.145 (SE 0.075)
1016 0.049 (SE 0.030) 0.002 0.074 (SE 0.029) < 0.001
359 − 0.134 (SE 0.048) − 0.200 (SE 0.049)
-0.4 -0.2 0.0 0.2 0.4 -0.4 -0.2 0.0 0.2 0.4
6–month diagnosis of psychopathology
Sexual interest**
Benzodiazepine use
Fear Questionnaire
Unadjusted Adjusted*Variables
No. Mean (SE) P Mean (SE) P
1–month diagnosis versus never–diagnosis of psychopathology 
Antidepressant use
Inventory of depressive symptomatology
Beck’s Anxiety Inventory
The size of each square is proportional to the number of participants; horizontal lines indicate standard errors.
Standard scores were calculated as the mean of z-scores of the morning and evening testosterone levels, within each sex.
P values are for the difference between the groups by analysis of variance.
⁎Adjusted for age, years of education, smoking status, prevalent cardiovascular disease, and northern European ancestry (as well as SSRI use [2 categories] when appropriate).
⁎⁎Sexual interest was assessed with item 22 of the Inventory of Depressive Symptomatology Self Report (IDS-SR).
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ered libido and difﬁculties with sexual arousal or orgasm [8–10].
These side effects normally continue for as long as the individual is
taking the medication and may partly be explained by increased pro-
lactin levels in some cases [80], that subsequently may also induce
gynecomastia and galactorrhoea. As androgens are pivotal for sexual
function, we were interested in the relationship between antidepres-
sant use and testosterone. Remarkably, we found that SSRI users hadhigher salivary testosterone levels versus participants who did not use
antidepressants,which is hard to reconcilewith their sexual side effects,
although SSRIs may have induced androgen antagonism or the higher
testosterone levels may be associated with treatment-induced in-
creases in prosocial behavior. The mechanisms of these side effects are
likely complex, involving not only endocrine (e.g., prolactin and sex
hormonal) but also directly effects on the central and peripheral ner-
vous systems involved in sexual function. Besides systemic effect on
Social phobia (SO) score
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for linear trend
in women
≤5 6−10 11−15 16−20 11−25 26−30 31−35 ≥36
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P<0.001
P=0.16
Fig. 1. Themean standard scores (with error bars representing standard errors) formorning and evening salivary testosterone levels, according (Box A) to the kind of antidepressant used
inmen andwomen combined, and (Box B) social phobia (SO) subscale score (part of the Fear Questionnaire) inwomen only. The black reference line shows themean score in non-users
of antidepressants. The size of each square is proportional to the number of participants. Vertical lines indicate standard errors. Scores are adjusted for sex (when appropriate), age, men-
strual status, years of education, smoking status, prevalent cardiovascular disease, and northern European ancestry. In Box B, testosterone valueswere additionally adjusted for SSRI use. P
values are (Box A) by analysis of covariance (compared to the non-user reference group), or (Box B) for linear trend in analysis of covariance. AD denotes antidepressant; SSRI denotes
selective serotonin reuptake inhibitors; TCA denotes tricyclic antidepressants.
211E.J. Giltay et al. / Journal of Psychosomatic Research 72 (2012) 205–213the circulating free testosterone level, SSRIs (and current smoking)may
have had a local effect on salivary glands, as antidepressants reduce the
salivary ﬂow through muscarinic acetylcholine receptor occupancy, in-
ducing the common complaint of a dry mouth. But effects such as a dry
mouth are more commonly observed during TCA use, which in our
study was not associated with higher testosterone levels [81].
Our study had some limitations. First, Salivettes were used for the
assessment of salivary testosterone, where a passive drooling device
would have been preferable. Since we observed a systematic eleva-
tion, all Salivette samples need to be collected and handled in the
same way in order to yield reliable statistical results as done in the
present study. As the difference in results was non-random (i.e.,
higher levels of testosterone using Salivettes as compared to passive
drool saliva samples but with a strong correlation), the internal valid-
ity of this study was high. Second, our analyses were cross-sectional
and therefore cannot indicate the causal direction. Third, we needed
to rely on saliva sampling at the homes of the participants, but as
we pooled either four or two saliva samples, compliance and timing
with the sampling instructions seemed less of an issue. Fourth, most
participants had "(either remitted or current)" anxiety or depressive
disorders, and therefore the control group without any lifetime psy-
chiatric diagnosis was relatively small. Nevertheless, noncompliance
with instructions could have resulted in some measurement error.
The CV of testosterone was around 10%, which error may have biased
our ﬁndings somewhat toward the null hypothesis. All saliva samples
were visually inspected for potential discoloration but not tested bio-
chemically for potential blood contamination [14]. The strengths of
our study included the large sample size, the ‘gold standard’ use of
multiple samples that were combined [11], and the inclusion of pa-
tients with several anxiety disorders. We also conﬁrmed ﬁndings of
low testosterone levels found in participants who were female,
using oral contraceptives, and were older, and high testosterone
levels found in participants who smoke, which support the validity
of salivary testosterone as a measure of androgenic activity.
We conclude that saliva samples are useful for non-invasive screen-
ing purposes. Salivary testosterone levels were signiﬁcantly lower in fe-
male patients with depression, generalized anxiety disorder, social
anxiety disorder, and agorophobia. These ﬁndings stress the role of tes-
tosterone in social affective symptomatology in women. Future studies
should explore whether testosterone treatment or augmentation is
beneﬁcial and safe not only in male but also in female patients with
low androgenic status.Conﬂict of interest
None.
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